

- Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007). Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. *Clinical Pharmacology & Therapeutics*, 81(2), 194-204.
- Lennernäs, H. (2003). Clinical pharmacokinetics of atorvastatin. *Clinical pharmacokinetics*, 42(13), 1141-1160.
- Lennernäs, H., & Fager, G. (1997). Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. *Clinical pharmacokinetics*, 32(5), 403-425.
- Libby, P., & Aikawa, M. (1998). New insights into plaque stabilisation by lipid lowering. *Drugs*, 56(1), 9-13.
- Liu, D., Jiang, J., Zhou, H., & Hu, P. (2008). Quantitative Determination of Atorvastatin and Parahydroxy Atorvastatin in Human Plasma by LC—MS—MS. *Journal of chromatographic science*, 46(10), 862-866.
- Maddigan, S. L., Feeny, D. H., Majumdar, S. R., Farris, K. B., & Johnson, J. A. (2006). Understanding the determinants of health for people with type 2 diabetes. *American Journal of Public Health*, 96(9), 1649.
- Maron, D. J., Fazio, S., & Linton, M. F. (2000). Current perspectives on statins. *Circulation*, 101(2), 207-213.